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Introduction
The age- standardized incidence rate for pancreatic cancer 
(PC) in men has increased by 25% from 1957 to 2011 
in Finland (http://www.cancer.fi/syoparekisteri/en/). The 
average age at diagnosis for PC is 69 years in Nordic 
males and 72 years in females. The average age at diag-
nosis for chronic pancreatitis (CP) is lower, 40–50 years, 
but there is an overlap in age, and the differential diag-
nosis between CP and PC can be very difficult. Clinical 
features, imaging changes and macroscopic appearance of 
CP may be difficult to differentiate from PC and a special 
challenge may be with paraduodenal and autoimmune 
pancreatitis because they closely resemble those of pan-
creatic ductal adenocarcinoma (PDAC).
There is no reliable non- invasive method to differentiate 
PC and CP at the moment and invasive methods such 
as needle biopsies are neither complication- free nor 
reliable.
The only established serum marker for pancreatitis is 
CA 19- 9 with a sensitivity and specificity of 68% and 
70% in differentiating between benign and malignant masses 
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Abstract
Finland ranks sixth among the countries having highest incidence rate of pan-
creatic cancer with mortality roughly equaling incidence. The average age of 
diagnosis for pancreatic cancer is 69 years in Nordic males, whereas the average 
age of diagnosis of chronic pancreatitis is 40–50 years, however, many cases 
overlap in age. By radiology, the evaluation of a pancreatic mass, that is, the 
differential diagnosis between chronic pancreatitis and pancreatic cancer is often 
difficult. Preoperative needle biopsies are difficult to obtain and are demanding 
to interpret. New blood based biomarkers are needed. The accuracy of the only 
established biomarker for pancreatic cancer, CA 19- 9 is rather poor in differ-
entiating between benign and malignant mass of the pancreas. In this study, 
we have performed mass spectrometry analysis (High Definition MSE) of serum 
samples from patients with chronic pancreatitis (13) and pancreatic cancer (22). 
We have quantified 291 proteins and performed detailed statistical analysis such 
as principal component analysis, orthogonal partial least square discriminant 
analysis and receiver operating curve analysis. The proteomic signature of chronic 
pancreatitis versus pancreatic cancer samples was able to separate the two groups 
by multiple statistical techniques. Some of the enriched pathways in the prot-
eomic dataset were LXR/RXR activation, complement and coagulation systems 
and inflammatory response. We propose that multiple high- confidence biomarker 
candidates in our pilot study including Inter- alpha- trypsin inhibitor heavy chain 
H2 (Area under the curve, AUC: 0.947), protein AMBP (AUC: 0.951) and 
prothrombin (AUC: 0.917), which should be further evaluated in larger patient 
series as potential new biomarkers for differential diagnosis.
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in the pancreas at the cutoff of 37 U/mL [1]. Increasing 
the cutoff increases the specificity markedly but sensitivity 
goes down markedly. New sensitive and specific biomarkers 
for differentiating these two diseases are desperately needed 
in the clinic. High throughput plasma proteomics can 
provide biomarker candidates which differentiate between 
the two diseases. Previously, some proteomic studies have 
been conducted to find biomarkers for pancreatic cancer 
which support and validate current study [2–6].
We have used high definition MSE (HDMSE) methodol-
ogy to compare chronic pancreatitis and pancreatic cancer 
in serum samples. We have quantitated 291 proteins 
including both classes of the samples. All protein abun-
dances were analyzed separately between the PC and CP 
patients. Data were further analyzed by principal com-
ponent analysis (PCA) and orthogonal partial least square 
discriminant analysis was employed to classify the samples 
and find out the most significantly differing proteins 
between the patient groups. We propose multiple high- 
confidence target biomarkers which are able to classify 
the two diseases into separate groups.
Materials and Methods
Patient samples
Preoperative serum samples according to the routine of 
the hospital laboratory were collected from 22 patients 
with pancreatic cancer and 13 patients with chronic pan-
creatitis. Of the patients with pancreatic cancer, all under-
went pancreaticoduodenal resection with curative intent. 
Of the patients with chronic pancreatitis 10 patients had 
alcohol- induced chronic pancreatitis and three had auto-
immune pancreatitis. Six patients underwent pancreati-
coduodenal resection and four patients, resection of the 
cauda or cauda and corpus, because malignancy could 
not be excluded based on preoperative investigations. In 
two patients the diagnosis of chronic pancreatitis was 
known before serum sampling. All sera were stored in 
aliquots of 1 mL at −80°C until used for further process-
ing described below. The study was approved by the 
Surgical Ethics Committee of Helsinki University Hospital 
(Dnro HUS 226/E6/06, extension TMK02 §66 17.4.2013). 
An informed written consent was obtained from all patients.
Further processing and trypsin digestion
Serum samples were thawed and used for TOP 12 protein 
depletion using the TOP12 protein depletion kit (Pierce, 
ThermoFisher) according to the manufacturer’s instruc-
tions. Total protein concentration was determined in 
TOP12 protein depleted serum with Pierce BCA assay kit 
(Pierce, ThermoFisher). Serum equivalent to 100 μg protein 
was aliquoted and dried by speedvac (Savant, 
ThermoFisher). The resulting dried serum was dissolved 
35 μL in 50 mmol/L Tris buffer, pH 7.8 containing 6M 
urea. After the protein dissolved, 1.8 μL of 200 mmol/L 
DTT was added to the samples and allowed to shake at 
RT for 1 h. Further, 7 μL of iodoacetamide (200 mmol/L 
stock solution) was added to the samples and they were 
further allowed to shake at RT for 1 h. After alkylation, 
to quench excess iodoacetamide and prevent overalkylation 
7 μL of DTT (200 mmol/L) was added to samples and 
again shaken for 1 h at RT. Samples were diluted by 
adding 270 μL of MQ water and trypsin was added at 
1:50 trypsin:protein ratio and digestion was allowed to 
occur at 37°C overnight. Following the digestion, 30 μg 
protein equivalent of samples were cleaned with C18 spin 
columns (Pierce, ThermoFisher). Resulting elution from 
C18 columns was dried and dissolved in 86 μL of 0.1% 
formic acid containing 12.5 fmol/μL of Hi3 spike- in stand-
ard peptides (Waters, MA, USA) for quantification.
Liquid chromatography- mass spectrometry 
(LC- MS) and quantification
UPLC- MS
A quantity of 4 μL samples (equivalent to ~1.4 μg total 
protein) were injected to nano Acquity UPLC (Ultra 
Performance Liquid Chromatography) - system (Waters 
Corporation, MA, USA). TRIZAIC nanoTile 85 μm × 
100 mm HSS- T3u wTRAP was used for separation before 
mass spectrometer. Samples were loaded, trapped and washed 
for two minutes with 8.0 μL/min with 1% B. The analytical 
gradient used is as follows: 0–1 min 1% B, at 2 min 5% 
B, at 65 min 30% B, at 78 min 50% B, at 80 min 85% 
B, at 83 min 85% B, at 84 min 1% B and at 90 min 1% 
B with 450 nL/min. Buffer A: 0.1% formic acid in water 
and Buffer B: 0.1% formic acid in acetonitrile.
Data were acquired in DIA (data independent acquisi-
tion) fashion using HDMSE mode with Synapt G2- S 
HDMS (Waters Corporation, MA, USA). The collected 
data range was 100–2000 m/z, scan time one- second, IMS 
wave velocity 650 m/s, collision energy was ramped in 
trap between 20 and 60 V. Calibration was done with 
Glu1- Fibrinopeptide B MS2 fragments and as a lock mass, 
Glu1- Fibrinopeptide B precursor ion was used during the 
runs. The samples were run as triplicates and further 
analysis was done with, Progenesis QI for Proteomics – 
software (Nonlinear Dynamics, Newcastle, UK).
Data analysis
Data analysis was performed as previously described [7]. 
Briefly, the raw files were imported to Progenesis QI for 
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proteomics software (Nonlinear Dynamics, Newcastle, UK) 
using lock mass correction with 785.8426 m/z, correspond-
ing to doubly charged Glu1- Fibrinopeptide B. Default 
parameters for peak picking and alignment algorithm were 
used. The software facilitated the peptide identification 
with Protein Lynx Global Server and label- free quantifica-
tion [8]. The peptide identification was done against 
Uniprot human FASTA sequences (UniprotKB Release 
2015_09, 20205 sequence entries) with (CLPB_ECOLI 
(P63285)), ClpB protein sequence inserted for label- free 
quantification. Modifications used were as follows: fixed 
at cysteine (carbamidomethyl) and variable in methionine 
(oxidation). Trypsin was used as digesting agent and one 
missed cleavage was allowed. Fragment and peptide error 
tolerances were set to auto and FDR to less than 4%. 
One or more ion fragments per peptide, three or more 
fragments per protein and one or more peptides per pro-
tein were required for ion matching. These are default 
parameters in the software.
The identified proteins are grouped as one according 
to parsimony principle and also peptides unique to the 
protein are reported. Parsimony principle states that pro-
tein hits are reported as the minimum set that accounts 
for all observable peptides. Progenesis QI for proteomics 
does not take a strict parsimonious approach because of 
over- stringency as has been pointed out before [9]. 
However, for resolution of conflicts, if two proteins contain 
some common peptides, protein with fewer peptides is 
subsumed into the protein with higher number of peptides 
which are a superset of the subsumed protein’s peptides. 
All relevant proteins are listed as a group under the lead 
protein with greatest coverage or the highest score when 
the coverages of two or more proteins are equal. 
Quantitation is performed using the lead identity peptide 
data. More details about this approach can be found on 
the software website (www.nonlinear.com).
The ANOVA calculation assumes that the conditions 
are independent and applies the statistical test that assumes 
the means of the conditions are equal. The label- free 
protein quantitation was done with Hi- N method [8]. 
In every injection the sample contained also 50 fmol of 
six CLPB_ECOLI (P63285, ClpB protein) peptides (Hi3 
E. coli Standard, Waters). Hi3 peptides are used for 
normalizing the peptide abundancies and relative quan-
titation was based on all the non- conflicting peptides 
found. The peptide ranking is done across all the runs. 
The abundancies of the peptides are averaged to provide 
a signal to the protein. Workings of the Progenesis soft-
wares have been described in details on the software 
website (www.nonlinear.com) and also in published lit-
erature [10]. Differences between controls and cases were 
evaluated with ANOVA on a protein- to- protein basis. 
Principle component analysis was performed with 
Progenesis QI for proteomics. Analyse- It program (with 
Microsoft Excel) was used for calculating area under the 
curve (AUC) values of ROC curves with all the default 
parameters.
Orthogonal partial least square modeling 
and discriminant analysis (OPLS- DA)
OPLS- DA modeling for pancreatitis and pancreatic cancer 
patients was performed with ropls [11] R package. Quality 
metrics, variable importance in projection (VIP), permuta-
tion diagnostics (1000 random permutations) and detection 
of outliers were calculated within the rolps package. One 
predictive component and 1–4 orthogonal components 
were used. To find out most influential proteins for sepa-
ration of patient groups, proteins with VIP>1 and uni-
variate P- value < 0.05 adjusted for false discovery rate 
[12] were selected. As an alternate method to find out 
most influential proteins, a S- plot with loadings of each 
protein on the X- axis and correlation of scores to mod-
eled X- matrix (p(corr)[1]=Corr(t1,X), t1 = scores in the 
predictive component) on Y- axis was constructed. Proteins 
with absolute value of loadings over 0.1 and absolute 
values of correlations over 0.7 were selected. A sample 
was considered as a possible outlier, if score distance 
exceeded SQRT(χ2(0.975)). The variables were standard-
ized by mean centering and unit variance scaling. More 
than two unique peptide and a confidence score of more 
than 4.5 was required for proteins to be included in the 
OPLS- DA model. This filtering based on confidence score 
is based on previous work [13].
Pathway analysis
Integrated Molecular Pathway Level Analysis (IMPaLA) 
was used for pathway over representation analysis. The 
method and rationale behind the approach has been pub-
lished previously [14]. By default, if no background list 
is supplied, the software uses all the entities present in 
all the pathways as background. Ingenuity pathway analysis 
(Ingenuity Systems, Redwood City, CA) was used for 
performing core analysis on the proteomic dataset with 
default parameters of the software. The results (canonical 
pathways) are presented in the results section as a figure. 
All the identified proteins were fed into IPA as input.
Data repository
The raw files were converted with MSConvert 
(ProteoWizard) to mzML- files. The mass spectrometry 
proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE [15] partner 
repository with the dataset identifier PXD005144.
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Results
Metadata
Twenty two pancreatic cancer and 13 chronic pancreatitis 
samples were analyzed in this study. In the CP group, 
three patients had autoimmune pancreatitis, and 10 had 
alcohol- induced chronic pancreatitis. Age of the patients 
in the PC group ranged from 54 to 79 and in the CP 
group from 42 to 74. Complete clinical features of the 
patients including grade of the tumor, T and N stage, 
gender and age are given in Table S1. One of the samples 
(autoimmune pancreatitis) was excluded from the analysis 
(due to technical reasons) as the chromatographic align-
ment of the technical replicates was not good and it 
stacked further aside from other samples in the PCA. 
This sample is marked in the Table S1.
Protein identification
We analyzed PC and CP samples by HDMSE and quanti-
fied 653 proteins from serum including proteins with 
minimum one unique peptide. Two hundred and ninety 
proteins were quantified with two or more unique peptides. 
Confidence score of identification ranged from 4084.212 
to 3.913. Only 11 proteins had the confidence score less 
than 4.6. Fold changes ranged from 1369.4 to 1.001 when 
PC has the higher mean and 236.5 to 1.004 when CP had 
the higher mean. One protein was found only in CP and 
five only in PC. Hundred and sixty- four proteins passed 
the cutoff of 0.05 of ANOVA P value when the higher 
mean was set to CP and 102 when the higher mean was 
set to PC. The complete data of all the proteins including 
various parameters such as ANOVA P values are given in 
Table S2. Our main criterion for differing proteins between 
the two classes was ANOVA P values and many proteins 
have P values higher than 0.05 despite having big fold 
change. Such proteins are not considered to be different.
Principal component analysis (PCA)
PCA was performed using the software Progenesis QI for 
Proteomics. This analysis determines the main axis of 
variation in the quantities of individual proteins which 
can point out the outliers. This method is also suitable 
to study the technical replicates as they should be close 
to each other on the PCA biplot. PCA biplot can tell 
the difference between amounts of variation among two 
classes of samples and present it in a visual manner. PCA 
of these CP and PC is shown in Figure 1.
The upper panel in the Figure 1 is the PCA when all 
the proteins were considered for PCA, and it can be seen 
that samples already have the tendency to cluster into 
two classes. Some overlapping samples can also be seen 
between the two groups but majority of the samples from 
the two groups (CP and PC) fall apart on the biplot. 
When only the housekeeping proteins (fold change 1 to 
1.3) were considered for PCA (middle panel) there is an 
almost complete overlap between the two groups which 
is expected as these proteins do not differ much between 
the two classes. Further, when only the proteins, having 
ANOVA P values lower than 0.05 and fold change more 
than 2, were considered for PCA there is a clear separa-
tion of the two groups with only very few samples falling 
in the overlapping area. The better than moderate separa-
tion of PC and CP patients in PCA prompted us to delve 
deeper into the statistical analysis and we constructed a 
model which is described in the next section.
Orthogonal partial least square modeling 
and discriminant analysis (OPLS- DA)
OPLS method enables distinct modeling of the predictive 
or correlated variance to the factor of interest as well as 
the uncorrelated variance. OPLS is an extension of the 
PLS statistical modeling but performs better in terms of 
interpreting the data from the model [11]. It is particularly 
useful when the number of variables exceeds the number 
of samples and when there is multicollinearity among the 
variables. For constructing an OPLS- DA model, ropls pack-
age in “R” was used and as a first step the data was 
filtered. For the filtering of proteins, stringent parameters 
were used such as; only the proteins with more than two 
peptide count and more than two unique peptides with 
confidence score cutoff of 4.5 were considered for OPLS- DA 
modeling. These proteins are given in Table S3.
Multivariate model was built, using OPLS in ropls pack-
age, for each protein’s abundance. The scores plot for 
the model is shown in the Figure 2A. The model was 
built with one predictive and one orthogonal component. 
Black ellipse is the 95% confidence interval for the model 
and red and blue ellipses are the 95% of multivariate 
normal distribution for each class of samples.
Permutation testing was employed to establish the sig-
nificance of the R2Y and Q2Y values (Figure S1) and P 
values for both parameters can be found on the top of 
the graph (both being significant). Diagnostic plot (Figure 
S2) was used to highlight the observations to find out 
the samples which are further away from the projection 
plane.
Cutoff for the score distance is the vertical dotted line 
and patient numbered C10 and ×1 appear to be outliers 
(Figure 2A). These two samples are marked in the Table 
S1 in the remarks column, which is patient information 
table. To further assess whether the quality of the model 
(or fit, R2Y) or separation between the classes (Q2Y) can 
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be improved by removing the outliers, these two samples 
were removed and model was built again. After removing 
these two outliers, the model was built again and this 
time we called it improved model. Figure 2B shows the 
scores plot and the permutation testing is shown in Figure 
S1 of the rebuilt, Improved model.
For cross- validation, 80% of the data was used for the 
training of the model and 20% for the prediction, averag-
ing over 1000 randomly chosen training and prediction 
sets. We calculated the sensitivity and specificity of the 
prediction in the improved model using this approach 
and it was found to be 94% (95% CI: 93–95%) and 67% 
(95% CI: 65–68%), respectively. In the training series or 
in the full model sensitivity and specificity were both 100%.
To find out the proteins of interest, which were sig-
nificant sources of variation between the two classes, two 
approaches were taken (univariate vs. multivariate 
parameters plot and S- Plot). P value for the false discovery 
rate (pFDR, univariate parameter) and variable influence 
on projection (VIP, multivariate parameter) were calculated 
for all the proteins and plotted against each other (Fig. 3). 
To validate this list of significantly different proteins and 
to find the variable proteins by another method S- Plot 
was constructed (Fig. 4).
Nineteen significant proteins were found by pFDR versus 
the VIP plot in the initial model and 18 in the improved 
model. Fifteen proteins were found to be significant in the 
improved model S- Plot (Table 1). Most proteins were com-
mon in all three methods and can be seen in the Table 1.
Pathway analysis
Two tools were employed for pathway analysis namely 
IMPaLA and Ingenuity pathway analysis (IPA). Figure S3 
Figure 1. Principal component analysis (PCA). Blue dots are samples of chronic pancreatitis and cyan dots are samples of pancreatic cancer. Each 
sample was run in triplicates. Upper panel is when the PCA was performed on all proteins with one or more unique peptides and middle panel is when 
proteins having the fold change of 1.0- 1.3 between the two conditions (housekeeping proteins) were used for PCA. Lower panel depicts the PCA 
when proteins passing the cutoff of 0.05 for ANOVA were used for PCA.
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shows the pathway over- representation analysis by IMPaLA 
in two conditions; when the highest mean was set to CP 
and when the highest mean was set to PC. Only the 
pathways with P_genes and Q_genes values below 0.05 
were considered and Figure S3 shows the top 10 pathway 
enriched in both the lists of proteins. Various comple-
ment activation and coagulation pathways were the main 
pathways enriched in both the lists. However, P_genes 
and Q_genes values were better in PC list for these path-
ways compared to CP list. Fibrinolytic pathways were 
particular enriched in CP and not in PC list. In IPA core 
analysis, top biofunctions and diseases are shown in Figure 
S4. Inflammatory response, developmental disorder and 
immunological diseases were the top disorders enriched 
and cellular movement and lipid metabolism were among 
the top molecular functions enriched.
In the same analysis by IPA, multiple canonical path-
ways were enriched in the CP and PC proteomic dataset. 
These were LXR/RXR activation, acute phase signaling 
response and similar to IMPaLA analysis, complement 
and coagulation system. Some of the top canonical path-
ways are shown in Figure 5.
Receiver operating characteristic (ROC) curves
Proteins found most significantly different in initial and 
improved OPLS- DA model and S- Plot of OPLS- DA model 
were further used for ROC Curve analysis. This method 
Figure 3. Selection of influential proteins. Proteins which had variable importance in projection (VIP) >1 and P - values adjusted for multiple comparisons 
<0.05 were considered as influential proteins for the separation of pancreatic cancer and chronic pancreatitis patients. The vertical dotted line is cutoff 
0.05 for pFDR and horizontal dotted line is the cutoff 1 for VIP.
Figure 2. Multivariate modeling of pancreatic cancer (PC) and chronic pancreatitis (CP) patients using OPLS- DA. A. Score plot of model including all 
patients (the predictive component on the x- axis and the orthogonal component on the y- axis) B. Score plot of the model excluding two outlier 
patients (these patients are indicated in the Table S1). R2X and R2Y are proportion of predictor/response variation explained by the full model, 
respectively. Q2Y is predictive performance of the model, RMSEE is root mean squared error of estimation, pre is the number of predictive components, 
ort is number of orthogonal components.
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was utilized to validate the diagnostic value of the proteins 
found common to all three methods, results of which are 
presented in Table 1. All these proteins were compared 
with each other to get a list of unique proteins and com-
mon to all three techniques. These proteins were analyzed 
by ROC curve analysis and area under the curve (AUC), 
95% confidence interval and standard error were calculated 
as described in methods. The results are presented in Table 2.
The Highest AUC value was found for protein AMBP 
(AUC: 0.951) followed by Inter- alpha- trypsin inhibitor 
heavy chain H2 (AUC: 0.947). The lowest AUC for the 
proteins analyzed by ROC curve was for protocadherin 
alpha- 13, which was 0.841 which is also good value for 
AUC. These proteins can classify the samples into two 
categories by various methods.
Discussion
Pancreatic cancer is the eighth leading cause of death 
worldwide in men and ninth in women [16]. The inci-
dence rates are slightly higher in western industrialized 
world and lower in developing countries such as India 
and Nigeria. Cancer statistics have revealed that prognosis 
of pancreatic cancer has not improved in recent years 
(judged by the survival of the patients) compared to other 
carcinomas [17]. Late diagnosis and aggressive nature of 
the cancer are responsible for the poor prognosis of PC. 
Delay in diagnosis is due to the several reasons including 
the prominent lack of suitable screening markers in an 
asymptomatic population.
CA 19- 9 and carcinoembryonic antigen (CEA) are the 
two most used serum biomarkers in PDAC, but are not 
suitable for screening an asymptomatic population [18, 
19]. They further have inadequate accuracy, even for pri-
mary diagnosis of symptomatic patients [18, 19]. Low 
sensitivity of the test necessitates invasive confirmatory 
examinations to confirm diagnosis. CA 19- 9 displays sen-
sitivity of 68% at 37 U/mL [1] and CEA 45%[20] and 
specificity of 70% and 81%, respectively [1, 20], figures 
that are too low for differential diagnosis from CP. It 
has to be noted that different studies report different 
values of sensitivity for CA 19- 9 due to the differential 
cutoff values used. CA19- 9 is now mainly accepted only 
as a follow- up and prognostic biomarker. Different types 
of CP cases closely resemble PC in clinical and imaging 
features and there is urgent need for novel biomarkers 
for differential and early diagnosis.
Serum is attractive for discovering screening and other 
type of biomarkers as it reflects organ- originated physi-
ological changes [21] and is easy to collect. Dynamic range 
of protein concentration in plasma or serum is 109 [22] 
and top 12 proteins constitute >95% of total plasma/
serum proteins. For this reason, it is very difficult to 
identify the low- abundant proteins which are potential 
biomarkers of various diseases. It is desirable to deplete 
high- abundant proteins to enable relatively deeper analysis 
of the serum proteome in health and disease. Twelve CP 
and 22 PC patients were retrospectively recruited for this 
study and serum protein profiles were studied by HDMSE 
using Synapt G2S HDMS system. After depletion of the 
top 12 most abundant proteins in human serum as 
described in methods, we quantified 291 proteins. However, 
Out of the total proteins identified, only some proteins 
(with peptide count of 2 or more and 2 or more unique 
peptides with confidence score of at least 4.5) were used 
for OPLS- DA modeling. R package ropls was employed 
to this end and data was normalized as described in 
methods. PCA visually presents the principal axes of vari-
ation in samples which helps in interpreting the separation 
of the groups. However, PCA with outliers present can 
give false results or lead to incorrect interpretations in 
classification of the samples. OPLS- DA scores plot and 
diagnostic plot can easily spot outliers in the data. These 
outliers, if included in the modeling reduce the optimum 
fit of the model to the data and lower the predictive 
accuracy of the statistical model. We found two outliers 
in the data and they were removed and the model was 
built again. This exercise markedly improved the 
Figure 4. Selection of influential proteins, S- plot Protein loadings (p1) 
on the X- axis and p(Corr)[1] on Y- axis. Proteins are coded by numbers. 
Loading vector was on the x- axis and correlation score on y- axis. An 
absolute cutoff value of the 0.1 for loading score and an absolute value 
of 0.7 for the correlation score was used to filter the significant proteins.
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separation quality of the model. These outliers performed 
normally as technical replicates however, the standardized 
expression profile for one of these samples (C10) was 
the highest in its group (Pancreatic cancer) and the other 
sample (×1) had the lowest expression profile in its group 
(Chronic pancreatitis). It could have been the reason for 
them to perform differently from the rest of the samples. 
Proteins of interest were found in the initial model by 
pFDR versus the VIP plot (univariate) and in improved 
model by univariate as well as multivariate manner (S- Plot). 
Most of the proteins found were common to all three 
lists suggesting that these proteins are the main sources 
of variation among the two disease groups. It also sug-
gests that these two methods are complementary to each 
other for feature selection in OMICS data which is in 
accordance with published literature [11].
Acylglycerol kinase, mitochondrial (AGK), is a lipid 
kinase which converts mono- and diacylglycerol to lysophos-
phatidic acid (LPA) and phosphatidic acid (PA) respectively 
[23]. Increase in LPA results in transactivation of epidermal 
growth factor receptor (EGFR) which leads to increased 
cell proliferation [23]. Overexpression of AGK can drive 
cancer cell growth and play an important role in patho-
physiology of cancer [23]. Protein AMBP was another 
protein which was commonly found in all two models 
and all three methods of feature selection to be signifi-
cantly different (Table 1). It has previously been found 
to be increased in pancreatic cancer [24]. However, there 
is no study hinting at its pathophysiological role in PC 
or CP. AMBP is an acute phase protein like others found 
in our study to be significantly different between PC and 
CP such as afamin, hemopexin and inter alpha- trypsin 
inhibitor heavy chain (ITIH) H1, H2, and H3. Acute 
phase response (APR) is critical for our bodies to respond 
to injury. However, sustained APR can lead to develop-
ment of chronic inflammation and tissue injury eventually 
giving rise to diseases such as cancer. Acute phase proteins 
also increase the blood flow to the site of injury [25] 
which can be hijacked by tumor microenvironment as a 
strategy to get access to sustained blood flow and nutri-
ents. Therefore, acute phase proteins such as those found 
in our study are not bystanders but potentially active 
players in tumorigenesis. They can make suitable biomark-
ers but it has to be considered with caution as they go 
up in several other conditions as well [26, 27]. Acute 
phase proteins may also reflect systemic inflammatory 
response seen in some of the cancer patients. For example, 
preoperative systemic inflammatory response (elevated 
CRP) in PDAC is an indicator of poor prognosis [28]. 
Preoperative CRP levels are also strong predictors of sur-
vival in colon cancer [29] and colorectal liver metastases 
[30]. Another protein found in all three methods of feature 
selection was Hepatocyte growth factor which is a ligand 
for c- MET. Cells in tumor microenvironment overexpress 
HGF and cancer cells have increased expression of c- MET 
and these events lead to promotion of various cancer- 
driving pathways [31, 32]. Our study gives insight into 
the biology of events driving the sustained growth and 
invasion of pancreatic cancer. Differential proteomics 
combined with statistical/mathematical analysis can provide 
biomarker candidates and also targets for therapeutic 
modulation of diseases. Two of the proteins, protein AMBP 
and ITI- H2 are known to be modified by chondroitin 
sulfate [33] and linked to each other. In protein AMBP, 
we have identified peptides which belong to only the 
Trypstatin part of the protein. Trypstatin is a separate 
chain which is a monomer. We did not identify any 
peptide from other parts of the protein AMBP (Bikunin) 
which, considering the limitations of the technological 
workflow used, excludes the possibility that we quantified 
the complex of ITIH2 heavy and light chain. In case of 
ITIH2, we have identified peptides only from the mature 
part of the chain while the chondroitin sulfated peptide 
is in propeptide region from which we did not identify 
any peptide. This again, despite the limitations, excludes 
the possibility that we have quantified the ITIH2 complex 
with light chain bound via chondroitin sulfate.
In the context of published literature, the study by Pan 
et al. quantified four plasma biomarkers of PC namely, 
14- 3- 3 sigma, gelsolin, lumican and tissue inhibitor of 
metalloproteinase 1 (TIMP- 1)[34]. When compared to 
our dataset, 14- 3- 3 sigma and TIMP- 1 were not identified 
in our study. The reason is the low concentration of 
these two proteins (approximately 50 ng/mL for 14- 3- 3 
sigma and 700 nag/mL for TTIMP- 1). The other two 
proteins gelsolin and lumican were confidently identified 
in our study. In the study by Pan et al. gelsolin had a 
fold change (FC) of 3.4 in PC versus CP and our study 
has the FC of 1.3 in PC vs CP. It was significantly dif-
ferent in both the studies (T- test in Pan et al. and Mann–
Whitney test in our study). However, Lumican, having 
the FC of 1.18 in our study (PC vs. CP) and 2.62 in 
Pan et al. (PC vs. CP) was not found to be significantly 
different in our study by Mann–Whitney test. It is to be 
noted that it was significantly different in our study by 
T- test but not by Mann–Whitney test. Pan et al. did the 
T- test for finding significance among the differences. Non- 
normal distribution dictates the use of non- parametric 
test and because of this reason, Mann–Whitney test was 
used in our study. Careful choice of statistical tests allows 
for more robust data analysis and chance of finding real 
differences are increased. However, none of these proteins 
passed the significance in OPLS- DA modeling as being 
significantly different proteins. T- test is a univariate method 
of data analysis while modern day proteomics datasets 
are more amenable to multivariate data analysis such as 
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OPLS- DA modeling. Out of the 653 proteins identified 
in our study, 257 are previously known to be present in 
plasma/serum while 396 proteins were identified for the 
first time. In one of the tissue proteomics study on PDAC 
tissue samples, 525 proteins were identified and 23 of 
them were common to our study including gelsolin, com-
plement C3 and lumican [35]. However, from one mouse 
study on PDAC tissues, the results did not overlap much 
[36]. In one study in pancreatic juice from CP and PC, 
some of proteins found to be differentially expressed also 
overlapped with our study from serum [37]. These pro-
teins were hemopexin, Beta- 2- glycoprotein 1, Alpha- 1B- 
glycoprotein and complement C3. Hemopexin as a 
glycoprotein biomarker from serum samples was also found 
Table 1. Selection of significantly different proteins.
Initial model VIP vs. pFDR Improved model VIP vs. pFDR Improved model S- Plot
Uniprot Accessions Protein Name PFDR VIP Uniprot Accessions Protein Name PFDR VIP Uniprot Accessions Protein Name P1 P(corr)[1]
P02760;S4R471 Protein AMBP 0.0003 2.1372 P04217 Alpha- 1B- glycoprotein 0.0008 1.8576 Q8IVV2;H7BZ41;J3QKX9 Lipoxygenase 
homology domain- 
containing protein 1
−0.1170 −0.9794
P19823;A0A087WTE1;Q5T985 Inter- alpha- trypsin inhibitor heavy chain H2 0.0005 1.9313 P00734;C9JV37;E9PIT3 Prothrombin 0.0008 2.0369 P26927;H7C0F8 Hepatocyte growth 
factor- like protein
−0.1330 −0.9445
P15313;C9JL73;C9JZ02 V- type proton ATPase subunit B, kidney 
isoform
0.0009 1.9485 P02760;S4R471 Protein AMBP 0.0012 2.1869 P15313;C9JL73;C9JZ02 V- type proton ATPase 
subunit B, kidney 
isoform
0.1370 0.9313
P26927;H7C0F8 Hepatocyte growth factor- like protein 0.0021 2.2957 P19823;A0A087WTE1;Q5T985 Inter- alpha- trypsin inhibitor 
heavy chain H2
0.0012 2.2491 P00734;C9JV37;E9PIT3 Prothrombin 0.1200 0.8786
P36955;I3L107;I3L1U4;I3L2R7;I3L3
Z3;I3L425;I3L4F9;I3L4N7;I3L4Z0
Pigment epithelium- derived factor 0.0021 1.7997 P15313;C9JL73;C9JZ02 V- type proton ATPase 
subunit B, kidney isoform
0.0029 2.3420 P05156;D6R9Z8;E7ETH0;G3XAM2 Complement factor I 0.1150 0.8704
P04217 Alpha- 1B- glycoprotein 0.0034 1.5699 P02790;Q9BS19;Q9NPA0 Hemopexin 0.0039 2.1569 P02743 Serum amyloid 
P- component
0.1300 0.8326
P00734;C9JV37;E9PIT3 Prothrombin 0.0043 1.6451 P36955;I3L107;I3L1U4;I3L2R7; 
I3L3Z3;I3L425;I3L4F9;I3L4N7; 
I3L4Z0
Pigment epithelium- 
derived factor
0.0067 2.0018 P43652 Afamin 0.1130 0.8184
P19827;F8WAS2;H7C0N0;H7C5I0 Inter- alpha- trypsin inhibitor heavy chain H1 0.0043 1.9809 P26927;H7C0F8 Hepatocyte growth 
factor- like protein
0.0086 2.2709 P01031 Complement C5 0.1080 0.8001
P01024;E9PJV1;E9PR27;M0QYC
8;O95568
Complement C3 0.0069 1.6420 P19827;F8WAS2;H7C0N0;H7C5I0 Inter- alpha- trypsin inhibitor 
heavy chain H1
0.0086 2.2428 Q9Y5I0;C9JA99;D6RA20;Q9UN74;
Q9UN75;Q9Y5H5;Q9Y5H7;Q9Y5
H8;Q9Y5H9;Q9Y5I3;Q9Y5I4
Protocadherin 
alpha- 13
0.1060 0.7860
P05155;H0YCA1;H9KV48 Plasma protease C1 inhibitor 0.0086 1.9650 P02743 Serum amyloid 
P- component
0.0110 2.2131 P19823;A0A087WTE1;Q5T985 Inter- alpha- trypsin 
inhibitor heavy chain 
H2
0.1320 0.7748
P05156;D6R9Z8;E7ETH0;G3XAM2 Complement factor I 0.0107 1.7204 P01024;E9PJV1;E9PR27;M0QYC8; 
O95568
Complement C3 0.0110 1.9340 P36955;I3L107;I3L1U4;I3L2R7;I3L3
Z3;I3L425;I3L4F9;I3L4N7;I3L4Z0
Pigment epithelium- 
derived factor
0.1170 0.7672
Q8IVV2;H7BZ41;J3QKX9 Lipoxygenase homology domain- containing 
protein 1
0.0161 1.7367 E9PG39;E9PC15;Q53H12 Acylglycerol kinase, 
mitochondrial
0.0139 1.8189 P19827;F8WAS2;H7C0N0;H7C5I0 Inter- alpha- trypsin 
inhibitor heavy chain 
H1
0.1320 0.7499
Q6ZRR7;H3BUS4 Leucine- rich repeat- containing protein 9 0.0161 1.7785 Q06033;A0A087WW43;E7ET33 Inter- alpha- trypsin inhibitor 
heavy chain H3
0.0139 1.8199 P02749;J3KS17;J3QLI0;J3QRN2 Beta- 2- glycoprotein 1 0.1150 0.7322
P43652 Afamin 0.0161 1.8528 Q6ZRR7;H3BUS4 Leucine- rich repeat- 
containing protein 9
0.0276 1.8487 P02760;S4R471 Protein AMBP 0.1280 0.7236
P02790;Q9BS19;Q9NPA0 Hemopexin 0.0241 1.8158 P05156;D6R9Z8;E7ETH0;G3XAM2 Complement factor I 0.0276 1.9549 P02790;Q9BS19;Q9NPA0 Hemopexin 0.1270 0.7193
Q9C099 Leucine- rich repeat and coiled- coil 
domain- containing protein 1
0.0291 1.3278 P02749;J3KS17;J3QLI0;J3QRN2 Beta- 2- glycoprotein 1 0.0341 1.9661
P02743 Serum amyloid P- component 0.0291 1.6691 P05155;H0YCA1;H9KV48 Plasma protease C1 
inhibitor
0.0341 1.8136
P02749;J3KS17;J3QLI0;J3QRN2 Beta- 2- glycoprotein 1 0.0291 1.7742 P43652 Afamin 0.0422 1.9287
E9PG39;E9PC15;Q53H12 Acylglycerol kinase, mitochondrial 0.0424 1.5528
The OPLS- DA model was built initially and again after removing two outliers found in the initial model. Variable influence on projection (VIP) values 
were plotted against P value for the false discovery rate (pFDR) and significantly different proteins between the two disease conditions were selected 
by choosing a cutoff of 0.05 for pFDR and 1 for VIP. These proteins as well as the proteins found to be significantly different by S- Plot (P 1 cutoff value 
of 0.1 and P (Corr) [1] value of 0.7) are presented in the table with appropriate parametric values given for each protein.
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to be able to classify CP versus PC samples in another 
study [38]. Another study identifying fucosylated proteins 
as candidate biomarkers for PC versus CP classification 
found 14 proteins common with our study [39]. These 
proteins are Plasma protease C1 inhibitor, hemopexin, 
Alpha- 1B- glycoprotein, Inter- alpha- trypsin inhibitor heavy 
chain H2 and H1, Complement C5, Serum amyloid 
P- component, Complement factor I, Protein AMBP, Beta- 
2- glycoprotein 1, Prothrombin, Pigment epithelium- 
derived factor, Afamin and Complement C3. Other proteins 
suggested as candidate biomarkers in our study such as 
Hepatocyte growth factor- like protein and Acylglycerol 
kinase, mitochondrial among others are novel and pre-
sented for the first time to the best of our knowledge.
Table 1. Selection of significantly different proteins.
Initial model VIP vs. pFDR Improved model VIP vs. pFDR Improved model S- Plot
Uniprot Accessions Protein Name PFDR VIP Uniprot Accessions Protein Name PFDR VIP Uniprot Accessions Protein Name P1 P(corr)[1]
P02760;S4R471 Protein AMBP 0.0003 2.1372 P04217 Alpha- 1B- glycoprotein 0.0008 1.8576 Q8IVV2;H7BZ41;J3QKX9 Lipoxygenase 
homology domain- 
containing protein 1
−0.1170 −0.9794
P19823;A0A087WTE1;Q5T985 Inter- alpha- trypsin inhibitor heavy chain H2 0.0005 1.9313 P00734;C9JV37;E9PIT3 Prothrombin 0.0008 2.0369 P26927;H7C0F8 Hepatocyte growth 
factor- like protein
−0.1330 −0.9445
P15313;C9JL73;C9JZ02 V- type proton ATPase subunit B, kidney 
isoform
0.0009 1.9485 P02760;S4R471 Protein AMBP 0.0012 2.1869 P15313;C9JL73;C9JZ02 V- type proton ATPase 
subunit B, kidney 
isoform
0.1370 0.9313
P26927;H7C0F8 Hepatocyte growth factor- like protein 0.0021 2.2957 P19823;A0A087WTE1;Q5T985 Inter- alpha- trypsin inhibitor 
heavy chain H2
0.0012 2.2491 P00734;C9JV37;E9PIT3 Prothrombin 0.1200 0.8786
P36955;I3L107;I3L1U4;I3L2R7;I3L3
Z3;I3L425;I3L4F9;I3L4N7;I3L4Z0
Pigment epithelium- derived factor 0.0021 1.7997 P15313;C9JL73;C9JZ02 V- type proton ATPase 
subunit B, kidney isoform
0.0029 2.3420 P05156;D6R9Z8;E7ETH0;G3XAM2 Complement factor I 0.1150 0.8704
P04217 Alpha- 1B- glycoprotein 0.0034 1.5699 P02790;Q9BS19;Q9NPA0 Hemopexin 0.0039 2.1569 P02743 Serum amyloid 
P- component
0.1300 0.8326
P00734;C9JV37;E9PIT3 Prothrombin 0.0043 1.6451 P36955;I3L107;I3L1U4;I3L2R7; 
I3L3Z3;I3L425;I3L4F9;I3L4N7; 
I3L4Z0
Pigment epithelium- 
derived factor
0.0067 2.0018 P43652 Afamin 0.1130 0.8184
P19827;F8WAS2;H7C0N0;H7C5I0 Inter- alpha- trypsin inhibitor heavy chain H1 0.0043 1.9809 P26927;H7C0F8 Hepatocyte growth 
factor- like protein
0.0086 2.2709 P01031 Complement C5 0.1080 0.8001
P01024;E9PJV1;E9PR27;M0QYC
8;O95568
Complement C3 0.0069 1.6420 P19827;F8WAS2;H7C0N0;H7C5I0 Inter- alpha- trypsin inhibitor 
heavy chain H1
0.0086 2.2428 Q9Y5I0;C9JA99;D6RA20;Q9UN74;
Q9UN75;Q9Y5H5;Q9Y5H7;Q9Y5
H8;Q9Y5H9;Q9Y5I3;Q9Y5I4
Protocadherin 
alpha- 13
0.1060 0.7860
P05155;H0YCA1;H9KV48 Plasma protease C1 inhibitor 0.0086 1.9650 P02743 Serum amyloid 
P- component
0.0110 2.2131 P19823;A0A087WTE1;Q5T985 Inter- alpha- trypsin 
inhibitor heavy chain 
H2
0.1320 0.7748
P05156;D6R9Z8;E7ETH0;G3XAM2 Complement factor I 0.0107 1.7204 P01024;E9PJV1;E9PR27;M0QYC8; 
O95568
Complement C3 0.0110 1.9340 P36955;I3L107;I3L1U4;I3L2R7;I3L3
Z3;I3L425;I3L4F9;I3L4N7;I3L4Z0
Pigment epithelium- 
derived factor
0.1170 0.7672
Q8IVV2;H7BZ41;J3QKX9 Lipoxygenase homology domain- containing 
protein 1
0.0161 1.7367 E9PG39;E9PC15;Q53H12 Acylglycerol kinase, 
mitochondrial
0.0139 1.8189 P19827;F8WAS2;H7C0N0;H7C5I0 Inter- alpha- trypsin 
inhibitor heavy chain 
H1
0.1320 0.7499
Q6ZRR7;H3BUS4 Leucine- rich repeat- containing protein 9 0.0161 1.7785 Q06033;A0A087WW43;E7ET33 Inter- alpha- trypsin inhibitor 
heavy chain H3
0.0139 1.8199 P02749;J3KS17;J3QLI0;J3QRN2 Beta- 2- glycoprotein 1 0.1150 0.7322
P43652 Afamin 0.0161 1.8528 Q6ZRR7;H3BUS4 Leucine- rich repeat- 
containing protein 9
0.0276 1.8487 P02760;S4R471 Protein AMBP 0.1280 0.7236
P02790;Q9BS19;Q9NPA0 Hemopexin 0.0241 1.8158 P05156;D6R9Z8;E7ETH0;G3XAM2 Complement factor I 0.0276 1.9549 P02790;Q9BS19;Q9NPA0 Hemopexin 0.1270 0.7193
Q9C099 Leucine- rich repeat and coiled- coil 
domain- containing protein 1
0.0291 1.3278 P02749;J3KS17;J3QLI0;J3QRN2 Beta- 2- glycoprotein 1 0.0341 1.9661
P02743 Serum amyloid P- component 0.0291 1.6691 P05155;H0YCA1;H9KV48 Plasma protease C1 
inhibitor
0.0341 1.8136
P02749;J3KS17;J3QLI0;J3QRN2 Beta- 2- glycoprotein 1 0.0291 1.7742 P43652 Afamin 0.0422 1.9287
E9PG39;E9PC15;Q53H12 Acylglycerol kinase, mitochondrial 0.0424 1.5528
1748 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
M. Saraswat et al.Proteomic profiling of pancreatic cancer serum
Pathway analysis mainly yielded the complement and 
coagulation cascades as enriched suggesting that they are 
the main perturbed pathways. Tissue factor, plasminogen 
and thrombin are the main coagulation- related proteins 
increased in PC [40–42]. Such a situation will lead to 
hypercoagulability- like state which is frequently observed 
in PC. It has been previously shown that thrombin: 
antithrombin complex and prothrombin fragment 1 + 2 
are increased in CP compared to healthy individuals but 
they are lower than in PC [43]. We have found, in our 
dataset, that prothrombin is increased in PC compared 
to CP with significant ANOVA P - value. In the OPLS- DA 
analysis the P value was also found to be significant for 
this protein (P = 0.00087 i.e., P < 0.001, see Table 1). 
Moreover, the prothrombin:antithrmobin ratio in our 
dataset in was 0.29 in CP while it was 0.34 in PC which, 
in the form of a trend, agrees well with the literature 
[43]. Our pathway analysis results show that P and Q 
values for coagulation pathways were much stronger 
for PC compared to CP. It could be a continuous 
 phenomenon and with increasing inflammation the 
 thrombin levels are increased and become highest for 
PC. In such a case, an optimum cutoff value can dif-
ferentiate PC from CP. Accordingly, AUC for thrombin 
was found to be 0.917 which is one of the highest in 
our dataset.
Figure 5. Canonical pathways enriched by core analysis in IPA. Top canonical pathways enriched by Ingenuity Pathway Analysis “Core analysis” are 
shown here. Straight orange vertical line running through the bars is threshold for P value for the particular pathway’s enrichment. Horizontal axis is 
the –log (P value) and vertical axis represents the given pathways.
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In conclusion, we report a number of potential bio-
markers with good statistical significance which can be 
used to differentiate PC versus CP. This is one of the 
most cumbersome and difficult clinical decisions in certain 
age groups. This pilot research paves the way for further 
studies to capitalize on the potential of the current one.
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Figure S1. Permutation testing of significance of R2Y and 
Q2Y values. A. Model including all patients, B. Model 
excluding two suspected outlier patients. 1000 permuta-
tions were performed.
Figure S2. Score distance versus the orthogonal distance 
plot for the dataset. The score distance cutoff line is the 
vertical dotted line, the orthogonal distance cutoff line is 
the horizontal dotted line. Any sample lying to the right 
of the vertical line or to the top of the horizontal line 
can be considered as outlier. 
Figure S3. Pathway over- representation analysis by 
IMPaLA. Pathway enrichment analysis using IMPaLA web 
based server was performed on two proteins list, one 
having highest mean in chronic pancreatitis (CP, left panel) 
and other having highest mean in pancreatic cancer (PC, 
right panel). P- value is given in blue bars while Q values 
are represented by red bars.
Figure S4. Molecular and cellular functions in IPA core 
analysis. Ingenuity pathway analysis “core analysis” was 
performed on the proteomic dataset and top molecular 
and cellular functions and disease and disorders are given 
here.
Table S1. Pancreatic cancer samples: All patients were 
M0, had no distant metastases.
Table S2. All the proteins quantified in the study with 
one or more unique peptides. Accession, peptide count 
(total peptides) and unique peptides, confidence score for 
identification, ANOVA p values for each protein, maxi-
mum fold change and the highest and lowest mean con-
ditions are given in the table along with the full protein 
name in the description heading.
Table S3. Proteins included in OPLS- DA modeling post- 
filtering based on two unique peptides and confidence 
score of more than 4.5.
